Back to search results

Observational Study on CALR-mutated MPN Cells

This observational study aims to understand why people with myeloproliferative neoplasm (MPN) who have a CALR gene mutation might have a different risk of blood clots compared to those with a JAK2 gene mutation. Researchers will look at the levels of two specific proteins, TLR 2 and TLR 4, in blood cells from people with CALR-mutated MPN, people with JAK2-mutated MPN, and healthy individuals. You might be able to join if you are 18 or older, have an MPN diagnosis, and have a CALR gene mutation. The study plans to enroll 35 participants. The main goal is to measure the levels of these proteins after 24 months.

Study design
This is an observational study designed to enroll 35 participants. It compares specific protein levels in people with CALR-mutated MPN, JAK2-mutated MPN, and healthy individuals.
What's involved
If you participate, you will have a research blood collection (about 3 ½ tablespoons) during a standard blood draw. Your medical history and current medications will also be collected once.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints, which are the expression levels of TLR 2 and TLR 4, will be measured at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06480591

Evaluation of the Pathobiology of CALR-mutated MPN Cells

Recruiting
Not specifiedAges 18+Observational
Wake Forest University Health Sciences
~35 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Blood Draw

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Expression levels of TLR 2 and TLR 4
Measured over 24 months

Conditions

Myeloproliferative Neoplasm

Explore related trials

Myeloproliferative NeoplasmCALR Gene

Where it's being run

2 sites across 1 states
North Carolina2

Study leadership

  • Aleksander Chojecki, MD · PRINCIPAL_INVESTIGATOR · Atrium Health Levine Cancer

Who to contact

Courtney Schepel
[email protected]
(980) 292-0817
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
Age ≥ 18 years at the time of enrollment
Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
CALR-positive genetic mutation

What this trial measures

  • Expression levels of TLR 2 and TLR 424 months

    Percentages of mononuclear cells expressing TLR 2 and TLR 4 will be calculated for each participant.